management of adverse events with newer agents for cll
Published 7 years ago • 549 plays • Length 22:35Download video MP4
Download video MP3
Similar videos
-
21:53
management of adverse events with newer therapeutic approaches
-
12:53
managing adverse events with new therapeutic approaches
-
13:55
debate: optimal approach for the management of cll patients with del(17p) - novel agents
-
27:18
novel treatment options in cll
-
22:08
role of chemotherapy in cll management
-
19:42
treatment options for the young cll patient with deletion 17p: do they need a different approach?
-
31:15
keynote lecture: managing side effects of io agents
-
14:13
debate: do we have enough data to eliminate chemotherapy from initial treatment for cll? - yes
-
1:08:25
cll treatment new options, more hope
-
23:25
velocity vlog: transforming the diagnosis and treatment of cll
-
20:40
cll: treatment for btki progressors
-
23:41
expert perspectives: chronic lymphocytic leukemia (cll)
-
24:17
combination of novel agents in cll: is this the final answer?
-
19:04
cll: sequencing decisions using current therapy options
-
25:38
cll: chemotherapy and ibrutinib based regimens
-
3:25
the management of btk-driven adverse events
-
4:22
management of btk class driven adverse events
-
35:31
cll: btk inhibitors in hematologic oncology pathways - pathway-guided choices
-
15:02
debate: will novel-agent based combination therapy become standard of care for cll? - no